R-Pharm
rpharm.ruTotal trials
75
Active
10
Phase 3
25
Total enrollment
18,262
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 24 of 24 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| RPH-104 | — | — | — | 7 | |||
| docetaxel | — | — | — | 4 | |||
| Cisplatin | — | — | — | — | 3 | ||
| RPH-002 | — | — | — | — | 2 | ||
| Erbitux® | — | — | — | — | 2 | ||
| trastuzumab | — | — | — | — | 2 | ||
| RPH-051 | — | — | — | — | — | 1 | |
| Perjeta® | — | — | — | — | — | 1 | |
| Subcutaneous | — | — | — | — | — | 1 | |
| SC injections of Placebo every 4 weeks (q4w), one injection of 0.4 mL | — | — | — | — | — | 1 | |
| RS-113, 160 mg | — | — | — | — | — | 1 | |
| RS-113, 240 mg | — | — | — | — | — | 1 | |
| RS-113, 320 mg | — | — | — | — | — | 1 | |
| Abiraterone | — | — | — | — | — | 1 | |
| Prednisolone | — | — | — | — | — | 1 | |
| Androgen deprivation therapy | — | — | — | — | — | 1 | |
| OKZ q4w | — | — | — | — | — | 1 | |
| RPH-035 | — | — | — | — | — | 1 | |
| Ocrevus® | — | — | — | — | — | 1 | |
| RPH-030 | — | — | — | — | — | 1 | |
| Vectibix® | — | — | — | — | — | 1 | |
| Irinotecan | — | — | — | — | — | 1 | |
| Calcium Folinate | — | — | — | — | — | 1 | |
| Fluorouracil | — | — | — | — | — | 1 |
Next readouts
- 2025-01
- 2025-09-29
- 2025-10-23
- 2026-01
- 2026-01-12
- 2026-05-14
- 2026-05-15
- 2026-09
- 2027-04-09
- 2028-12
Top conditions
- COVID-198
- Metastatic Breast Cancer8
- Rheumatoid Arthritis5
- Breast Cancer5
- Healthy4
- Head and Neck Squamous Cell Carcinoma3
- Cancer3
- Advanced Solid Tumors3
Frequently asked questions about R-Pharm
- How many clinical trials does R-Pharm have on ClinicalTrials.gov?
- R-Pharm is listed as the lead sponsor on 75 clinical trials in ClinicalTrials.gov, 10 of which are currently active (recruiting, enrolling, or ongoing).
- How many of R-Pharm's trials are in Phase 3?
- 25 of R-Pharm's trials are in Phase 3, spread across 24 active drug programs.
- What therapeutic areas does R-Pharm focus on?
- R-Pharm's most-studied conditions on ClinicalTrials.gov are COVID-19, Metastatic Breast Cancer, Rheumatoid Arthritis, Breast Cancer, Healthy.
- When are R-Pharm's next clinical trial readouts?
- R-Pharm has 10 upcoming primary-completion readouts tracked here; the soonest is “Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine”, expected around 2025-01.